Insight Molecular Diagnostics (IMDX) Equity Average (2016 - 2026)

Insight Molecular Diagnostics has disclosed Equity Average across 11 years of filings, most recently posting -$21.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at -$21.1 million, down 1950.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$21.1 million (down 1950.34% YoY), and the FY2025 annual result was -$21.9 million, down 633.78% from the prior year.
• Equity Average came in at -$21.1 million for Q1 2026 at Insight Molecular Diagnostics, down from -$20.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $80.0 million in Q3 2022 to a low of -$21.1 million in Q1 2026.
• The 5-year median for Equity Average is $17.1 million (2024), against an average of $24.7 million.
• Across the five-year window, Equity Average slipped 12.79% in 2022 and tumbled 1950.34% in 2026, its largest moves.
• Insight Molecular Diagnostics' Equity Average stood at $55.6 million in 2022, then plunged by 49.07% to $28.3 million in 2023, then plunged by 104.53% to -$1.3 million in 2024, then tumbled by 1486.42% to -$20.3 million in 2025, then fell by 3.68% to -$21.1 million in 2026.
• The last three Equity Average figures came in at -$21.1 million (Q1 2026), -$20.3 million (Q4 2025), and -$4.0 million (Q3 2025), per Business Quant data.